Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease, a serious hereditary kidney disease, presented preclinical data on the effects of a compound from its LoAc® pipeline on a model of ADPKD on 25 May 2024 at the European Renal Association Congress, held in Stockholm, Sweden.
May 28, 2024
· 2 min read
